The Fridley, Minnesota-based company designed the Onyx Frontier drug-eluting stent (DES) to build upon its Resolute Onyx DES. It uses the same stent platform as the Resolute Onyx and has an enhanced delivery system to increase acute performance in interventional coronary artery disease procedures.
The new drug-eluting stent has a dual-layer balloon, lower crossing profile and increased catheter flexibility. Its broad size matrix can treat patients ranging from 2mm to 5mm diameters, and it’s possible to expand its 4.5mm to 5mm sizes to 6mm to support extra-large vessels, including the left main.
“The Onyx Frontier DES launch demonstrates our commitment to interventional cardiologists by providing best-in-class products,” said Jason Weidman, SVP and president of Medtronic’s coronary and renal denervation business unit. “Following our launch in the US, we’re thrilled to provide hospitals across western Europe and the globe with the Onyx Frontier DES, which has been thoughtfully designed with physicians’ needs in mind. This launch furthers Medtronic’s goal of engineering the extraordinary, and we look forward to continuing to pursue innovation each day.”
The new drug-eluting stent received FDA approval in May and recently won CE mark approval in Europe. It has the same clinical data and indications of Resolute Onyx, including approval for bifurcation lesions, left main PCI and one month of dual antiplatelet therapy in high bleeding risk patients.
